Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.

Matteo Ruggeri; Antonio Bellasi; Filippo Cipriani; Donald Molony; Cynthia Bell; Domenico Russo; Biagio Di Iorio

doi:10.1007/s40620-014-0122-8

Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.

Matteo Ruggeri
, Antonio Bellasi
, Filippo Cipriani
, Donald Molony
, Cynthia Bell
, Domenico Russo
, Biagio Di Iorio

Università Cattolica del Sacro Cuore

Risultato della ricerca: Contributo in rivista › Articolo › peer review

8 Citazioni (Scopus)

Abstract

HEALTH ECONOMICS

Lingua originale	Inglese
pagine (da-a)	593-602
Rivista	American Journal of Nephrology
Volume	28
DOI	https://doi.org/10.1007/s40620-014-0122-8
Stato di pubblicazione	Pubblicato - 2015

Keywords

HEALTH ECONOMICS

Accesso al documento

10.1007/s40620-014-0122-8

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Ruggeri, M., Bellasi, A., Cipriani, F., Molony, D., Bell, C., Russo, D., & Di Iorio, B. (2015). Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study. American Journal of Nephrology, 28, 593-602. https://doi.org/10.1007/s40620-014-0122-8

@article{e5a009b9003443f4ad298a878971eb32,

title = "Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.",

abstract = "HEALTH ECONOMICS",

keywords = "HEALTH ECONOMICS, HEALTH ECONOMICS",

author = "Matteo Ruggeri and Antonio Bellasi and Filippo Cipriani and Donald Molony and Cynthia Bell and Domenico Russo and \{Di Iorio\}, Biagio",

year = "2015",

doi = "10.1007/s40620-014-0122-8",

language = "English",

volume = "28",

pages = "593--602",

journal = "American Journal of Nephrology",

issn = "0250-8095",

publisher = "S. Karger AG",

}

Ruggeri, M, Bellasi, A, Cipriani, F, Molony, D, Bell, C, Russo, D & Di Iorio, B 2015, 'Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.', American Journal of Nephrology, vol. 28, pagg. 593-602. https://doi.org/10.1007/s40620-014-0122-8

Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study. / Ruggeri, Matteo; Bellasi, Antonio; Cipriani, Filippo et al.
In: American Journal of Nephrology, Vol. 28, 2015, pag. 593-602.

Risultato della ricerca: Contributo in rivista › Articolo › peer review

TY - JOUR

T1 - Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.

AU - Ruggeri, Matteo

AU - Bellasi, Antonio

AU - Cipriani, Filippo

AU - Molony, Donald

AU - Bell, Cynthia

AU - Russo, Domenico

AU - Di Iorio, Biagio

PY - 2015

Y1 - 2015

N2 - HEALTH ECONOMICS

AB - HEALTH ECONOMICS

KW - HEALTH ECONOMICS

UR - http://hdl.handle.net/10807/63641

U2 - 10.1007/s40620-014-0122-8

DO - 10.1007/s40620-014-0122-8

M3 - Article

SN - 0250-8095

VL - 28

SP - 593

EP - 602

JO - American Journal of Nephrology

JF - American Journal of Nephrology

ER -

Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo